WO2002031198A3 - Genes lies au cancer utilises comme cibles pour la chimiotherapie - Google Patents

Genes lies au cancer utilises comme cibles pour la chimiotherapie Download PDF

Info

Publication number
WO2002031198A3
WO2002031198A3 PCT/US2001/031607 US0131607W WO0231198A3 WO 2002031198 A3 WO2002031198 A3 WO 2002031198A3 US 0131607 W US0131607 W US 0131607W WO 0231198 A3 WO0231198 A3 WO 0231198A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
disclosed
chemotherapy
targets
linked genes
Prior art date
Application number
PCT/US2001/031607
Other languages
English (en)
Other versions
WO2002031198A2 (fr
Inventor
Paul E Young
Stephen Horrigan
Zoe Weaver
Gregory A Endress
Original Assignee
Avalon Pharmaceuticals
Paul E Young
Stephen Horrigan
Zoe Weaver
Gregory A Endress
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals, Paul E Young, Stephen Horrigan, Zoe Weaver, Gregory A Endress filed Critical Avalon Pharmaceuticals
Priority to US10/399,225 priority Critical patent/US20040072192A1/en
Priority to AU2002213084A priority patent/AU2002213084A1/en
Priority to EP20010981443 priority patent/EP1399584A2/fr
Priority to CA 2425643 priority patent/CA2425643A1/fr
Priority to JP2002534562A priority patent/JP2004533206A/ja
Publication of WO2002031198A2 publication Critical patent/WO2002031198A2/fr
Publication of WO2002031198A3 publication Critical patent/WO2002031198A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention concerne des séquences de gènes liés au cancer, des séquences d'acides aminés dérivées et des méthodes destinées à analyser des agents antitumoraux potentiels sur la base de leur modulation de l'expression de ces gènes liés au cancer. La présente invention se rapporte également à des anticorps réagissant avec les polypeptides de l'invention, ainsi qu'à des méthodes destinées au diagnostic et au traitement du cancer au moyen de ces séquences de gènes. Ladite invention concerne enfin un nouveau gène et un nouveau polypeptide.
PCT/US2001/031607 2000-10-11 2001-10-11 Genes lies au cancer utilises comme cibles pour la chimiotherapie WO2002031198A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/399,225 US20040072192A1 (en) 2001-10-11 2001-10-11 Cancer-linked genes as targets for chemotherapy
AU2002213084A AU2002213084A1 (en) 2000-10-11 2001-10-11 Cancer-linked genes as targets for chemotherapy
EP20010981443 EP1399584A2 (fr) 2000-10-11 2001-10-11 Genes lies au cancer utilises comme cibles pour la chimiotherapie
CA 2425643 CA2425643A1 (fr) 2000-10-11 2001-10-11 Genes lies au cancer utilises comme cibles pour la chimiotherapie
JP2002534562A JP2004533206A (ja) 2000-10-11 2001-10-11 化学療法のための標的としてのガン関連遺伝子

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US23960500P 2000-10-11 2000-10-11
US23929700P 2000-10-11 2000-10-11
US23929400P 2000-10-11 2000-10-11
US60/239,605 2000-10-11
US60/239,294 2000-10-11
US60/239,297 2000-10-11
US23980600P 2000-10-12 2000-10-12
US23980500P 2000-10-12 2000-10-12
US23980200P 2000-10-12 2000-10-12
US60/239,802 2000-10-12
US60/239,806 2000-10-12
US60/239,805 2000-10-12
US24062200P 2000-10-16 2000-10-16
US60/240,622 2000-10-16
US24168200P 2000-10-19 2000-10-19
US24172300P 2000-10-19 2000-10-19
US60/241,682 2000-10-19
US60/241,723 2000-10-19
US24493200P 2000-10-31 2000-10-31
US60/244,932 2000-10-31

Publications (2)

Publication Number Publication Date
WO2002031198A2 WO2002031198A2 (fr) 2002-04-18
WO2002031198A3 true WO2002031198A3 (fr) 2003-12-31

Family

ID=27581180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031607 WO2002031198A2 (fr) 2000-10-11 2001-10-11 Genes lies au cancer utilises comme cibles pour la chimiotherapie

Country Status (5)

Country Link
EP (1) EP1399584A2 (fr)
JP (1) JP2004533206A (fr)
AU (1) AU2002213084A1 (fr)
CA (1) CA2425643A1 (fr)
WO (1) WO2002031198A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097408B2 (en) 2004-10-15 2012-01-17 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US7411045B2 (en) 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
US7651854B2 (en) 2003-02-26 2010-01-26 A & G Pharmaceutical, Inc. Methods for increasing the proliferation of B cells
EP1660010B1 (fr) 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Compositions et procedes pour le retablissement de la sensibilite au traitement par antagonistes vis-a-vis de her2
GB0328928D0 (en) * 2003-12-12 2004-01-14 Cancer Rec Tech Ltd Materials and methods relating to cell cycle control
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
JP2010511382A (ja) * 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028193A1 (fr) * 1996-01-30 1997-08-07 Melcorp Diagnostics, Inc. Compositions et procedes utiles dans la detection et/ou le traitement d'etats cancereux
US5855889A (en) * 1995-05-31 1999-01-05 Washington University Mammaglobin, a mammary-specific breast cancer protein
WO1999038972A2 (fr) * 1998-01-28 1999-08-05 Chiron Corporation Genes humains et produits ii d'expression genique
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
WO2001042467A2 (fr) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits et techniques d'identification, d'evaluation, et de prevention du cancer du col de l'uterus et therapie
WO2001060860A2 (fr) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes, compositions, kits, et procedes d'identification, d'evaluation, de prevention, et de traitement du cancer de la prostate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855889A (en) * 1995-05-31 1999-01-05 Washington University Mammaglobin, a mammary-specific breast cancer protein
WO1997028193A1 (fr) * 1996-01-30 1997-08-07 Melcorp Diagnostics, Inc. Compositions et procedes utiles dans la detection et/ou le traitement d'etats cancereux
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
WO1999038972A2 (fr) * 1998-01-28 1999-08-05 Chiron Corporation Genes humains et produits ii d'expression genique
WO2001042467A2 (fr) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits et techniques d'identification, d'evaluation, et de prevention du cancer du col de l'uterus et therapie
WO2001060860A2 (fr) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes, compositions, kits, et procedes d'identification, d'evaluation, de prevention, et de traitement du cancer de la prostate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 12 October 1999 (1999-10-12), CRKVENJAKOV R ET AL.: "Human gene expression product cDNA sequence SEQ ID No: 1355", retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AAZ13886 *
DATABASE EMBL [online] EBI; 14 June 2001 (2001-06-14), SCHLEGEL R ET AL: "Human cervical cancer marker nucleic acid 4635", XP002243432, retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AAH73361 *
DATABASE EMBL [online] EBI; 16 September 2002 (2002-09-16), SCHLEGEL R ET AL.: "Human prostate expression marker cDNA 24394", XP002243431, retrieved from HTTP://WWW.EBI.AC.UK Database accession no. ABV24403 *
DATABASE EMBL [online] EBI; 2 January 2000 (2000-01-02), ZHANG C. ET AL.: "Homo sapiens PRO2000 mRNA", XP002243375, retrieved from HTTP://WWW.EBI.AC.UK Database accession no. AF118088 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097408B2 (en) 2004-10-15 2012-01-17 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases

Also Published As

Publication number Publication date
EP1399584A2 (fr) 2004-03-24
JP2004533206A (ja) 2004-11-04
AU2002213084A1 (en) 2002-04-22
WO2002031198A2 (fr) 2002-04-18
CA2425643A1 (fr) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2003097803A3 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
WO2003101400A3 (fr) Gene lie au cancer comme cible de chimiotherapie
WO2003105758A3 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
WO2003104399A3 (fr) Gene lie au cancer servant de cible en chimiotherapie
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001030964A3 (fr) Acides nucleiques anticancereux et cibles proteiniques
WO2000050588A3 (fr) Genes associes a des maladies du colon
WO2000061622A3 (fr) Genes associes aux maladies du rein
EP0892048A3 (fr) XAF gènes et polypeptides et leur utilisation pour la modulation de l'apoptose
WO2002031198A3 (fr) Genes lies au cancer utilises comme cibles pour la chimiotherapie
AU2154801A (en) Method for linking molecular substances
WO1999067384A3 (fr) Genes associes au cancer de la prostate
WO2005035724A3 (fr) Genes lies au cancer en tant que cibles de chimiotherapie
PL327066A1 (en) Method of diagnosing and treating squamous cell carcinomas
WO2005019475A3 (fr) Proteine 2 inductible par l'hypoxie (hig2), nouvelle cible therapeutique potentielle de l'hypernephrome (rcc)
EP1038025A4 (fr) Modifications genetiques associees au cancer
WO2003076579A3 (fr) Gene associe au cancer utilise en tant que cible pour la chimiotherapie
WO2003097802A3 (fr) Gene lie au cancer utilise comme cible pour la chimiotherapie
WO2003104401A3 (fr) Gene lie au cancer cible en chimiotherapie
WO2003104438A3 (fr) Genes lies au cancer servant de cibles de chimiotherapie
WO2003076587A3 (fr) Genes lies au cancer utilises comme cibles ce chimiotherapie
WO2001000799A8 (fr) Nouvelle proteine et son adn
WO2003076571A3 (fr) Genes lies au cancer utilises comme cibles en chimiotherapie
WO2003097801A3 (fr) Gene associe au cancer utilise comme cible pour une chimiotherapie
WO2005062788A3 (fr) Proteines specifiques de la prostate exprimees dans le cancer et methodes d'utilisation associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002534562

Country of ref document: JP

Ref document number: 2425643

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001981443

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10399225

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001981443

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001981443

Country of ref document: EP